Kornimate/medical-research-clean huggingface dataset:
the effect of aerobic exercise in overweight and obese women

Conditions: Obesity; Overweight

Summary: study design the study was designed as a prospective controlled randomized trial. participants were randomly assigned to one of two groups. in the experimental group, participants (n = 17) received 8-week aerobic exercise intervention without nutrition modifications. in the control group, participants (n = 16) did not undergo any intervention and were instructed to maintain their regular physical activity and diet regime for 8 weeks. experimental measurements: anthropometric measurements, measurement of bdnf, cardiac autonomic responses, measurement of aerobic fitness, measurement of cognitive functions.


Eligibility criteria:
inclusion criteria: 1. obese women (bmi) \> 25 kg/m2; 2. exhibiting weight stability (body weight change \< 2 kg) for at least 2 months prior to enrollment; 3. with a sedentary lifestyle (regular exercise \< 1 h/week); 4. had no medical condition that would affect study results and limit physical activity; 5. not undergoing lactation; 6. who were not pregnant or postmenopausal.
the treatment and natural history of acromegaly

Conditions: Acromegaly; Pituitary Neoplasm

Summary: the purpose of this study is to investigate the treatment and natural history of acromegaly. we have a longstanding interest in acromegaly treatment, and a cohort that has been followed for 30 years, or more in some cases. we will continue to follow patients and recruit new patients for treatment and follow-up. blood and pituitary tumor tissue (when available through clinical care) will be saved for future analyses related to acromegaly.

the purpose of this study is to investigate the treatment and natural history of acromegaly. we have a longstanding interest in acromegaly treatment, and a cohort that has been followed for 30 years, or more in some cases. we will continue to follow patients and recruit new patients for treatment and follow-up.

Eligibility criteria:
* inclusion criteria: patients will be enrolled who are 18 years of age or over who are referred for care.

Keywords: acromegaly
automated anesthesia during bronchoscopy

Conditions: Anesthesia, General

Summary: the purpose of this study is to compare manual administration of propofol and remifentanil and dual closed-loop using bispectral index as the control variable during rigid bronchoscopy.

the bispectral index (bis) is an electroencephalogram-derived measure of anesthetic depth. we have built a combined closed-loop anesthesia system using bis as the control variable, two proportional-integral-differential control algorithms, a propofol and a remifentanil target-controlled infusion systems as the control actuators. a recent study has shown that such system is able to provide clinically adequate anesthesia. the aim of the present study is to assess the system during rigid bronchoscopy. two groups of patients are compared: one in which propofol and remifentanil are administered by the anesthesiologist using target-controlled infusion systems, and one in which propofol and remifentanil are administered automatically by the combined closed-loop anesthesia system. in both groups, the goal is to maintain bis between 40 and 60, the recommended range during anesthesia by the manufacturer. we expect the combined closed-loop anesthesia system group to do similar or better.

Eligibility criteria:
inclusion criteria: * patients undergoing rigid bronchoscopy under general anesthesia exclusion criteria: * pregnant women * allergy to propofol or remifentanil * neurological disorder * psychotrop treatment

Keywords: algorithms anesthesia, general/*methods anesthetics, intravenous/*administration & dosage drug delivery systems/*methods/statistics & numerical data electroencephalography/drug effects/*methods/ feasibility studies propofol/*administration & dosage remifentanil/*administration & dosage bronchoscopy/*methods prospective studies software
management of aorto-iliac infection with biointegral surgical no-react® bovine pericardial xenografts

Conditions: Aortic Diseases

Summary: aortic infections (ais), including aortic graft infections (agi) as well as mycotic aortic aneurysms (maa), are rare. the aim of this study is to present our experience with xenogeneic aortic and aortoiliac reconstructions using the biointegral surgical no-react® bovine pericardial graft.


Eligibility criteria:
inclusion criteria: * aortic infection * mycotic aneurysm * aortic graft infection exclusion criteria: * absence of signs of infection
spanish academy of dermatology and venereology (aedv) melanoma registry

Conditions: Melanoma

Summary: the goal of this patient registry is to describe risk factors for bad prognosis of melanoma in spain. the main questions it aims to answer are: * to describe socioeconomical individual risk factors associated with melanoma prognosis, such as gender, residence area or socioeconomic level. * to describe potentially modifiable characteristics of health care associated with prognosis, such as waiting times, type of centre that makes the diagnosis or use of teledermatology participants data will be gathered for analysis, without any change in the way that they are being treated.


Eligibility criteria:
inclusion criteria: * all consecutive patients with a diagnosis of invasive primary cutaneous melanoma in participating centres. exclusion criteria: * in-situ melanomas * non-cutaneous melanomas, * metastatic melanoma with unknown primary site.
controlled ovarian stimulation followed by timed intercourse or intrauterine insemination in infertile pcos patients

Conditions: Polycystic Ovary Syndrome

Summary: at the present the first options to induce ovulation in polycystic ovary syndrome with anovulatory infertility are clomiphene citrate (cc) and metformin. notwithstanding the effectiveness of cc and metformin alone or in a sequential or combined regimen, a percentage of patients ranging from 5% to 30% remain anovulatory. for these patients, the use of gonadotropins for controlled ovarian stimulation (cos) is indicated. moreover, to date it isn't clear if cos should be followed by timed intercourse (ti) or intrauterine insemination (iui). the aim of the present study will be to compare ti and iui in infertile pcos patients undergoing cos in terms of cost-benefit.

infertile pcos patients who remain anovulatory after cc or metformin treatment will be enrolled. all patients will receive gonadotropins in low-dose step-up protocol for cos, and randomized to receive three trials of ti (group a) or iui (group b). all patients eligible will undergo baseline assessment consisting of anthropometric, hormonal, and ultrasonographic evaluations. in all patients the cos will be obtained using highly purified urinary fsh in a low-dose step-up protocol, and both ti and iui will be performed after 35 hours from ovulation induction with human chorionic gonadotropin. during the study, the clinical and reproductive outcomes, the adverse experience will be evaluated in each patient. data will be analyzed using the intention-to-treat principle and a p value of 0.05 or less will be considered significant. continuous variables will be analyzed with the unpaired t test and general linear model for repeated measures analysis with bonferroni test for the post-hoc analysis as required. for categorical variables, the pearson chi-square and fisher's exact tests will be used. cumulative pregnancy rate, our primary end-point, will be calculated by the kaplan-maier method, and the differences between the two groups will be assessed with the log-rank test. cox proportional-hazards model will be used to calculate the hazard ratio for new pregnancy in both groups.

Eligibility criteria:
inclusion criteria: * polycystic ovary syndrome (using nih criteria) * anovulatory infertility (using who criteria) exclusion criteria: * age \ 35 years * severe obesity (bmi \>35) * neoplastic, metabolic, hepatic, and cardiovascular disorders or other concurrent medical illnesses * hypothyroidism, hyperprolactinemia, cushing's syndrome, and non-classical congenital adrenal hyperplasia * current or previous (within the last six months) use of oral contraceptives, glucocorticoids, antiandrogens, anti-obesity drugs, hormonal drugs * intention to start a diet or a specific program of physical activity * organic pelvic diseases * previous pelvic surgery * suspected peritoneal factor infertility * tubal or male factor infertility or sub-fertility

Keywords: gonadotropins infertility intrauterine insemination pcos timed intercourse treatment
use of a share decision making tool in the care of acute cystitis without risk of complication in primary care

Conditions: Cystitis

Summary: the aim of this trial is to demonstrate that when caring women with symptoms of acute cystitis without any risk of complication, general practitioner may use share decision making tool to help patients better understand the stakes of taking antibiotics.

each year, more than 2.000.000 patients visit their general practitioners for a acute cystitis. the scientific literature shows that acute cystitis without risk of complication cause complications, such as pyelonephritis, in a very rare cases. however, french guidelines systematically request an antibiotic therapy as soon as the diagnostic is confirmed with the only goal to lowering symptomatology. recent studies show that some informed women would like not to take antibiotics and pain-killers could be as effective as antibiotics. canadian studies assessing share decision making tools in patients with acute respiratory infection have shown that matching antibiotic treatment with the patient values lower such prescription without any impact on clinical outcomes . investigators aim to assess a similar strategy in patients with acute cystitis. this study will compare a group following french guidelines versus one using a share decision making tool to determine if, after being informed of the benefice and risk of this treatment, patient still want an antibiotic. targeting instead of systematic prescription will reduce antibiotic consumption. after diagnostic of acute cystitis to a woman between 18 and 65 years, investigators check if they filing all study criteria and ask for authorization to add them to the study. then they'll act following their group instruction, and get information (antibiotic prescription or not, score to the activity impairment assessment (aia) scale, score to satisfaction scale). then patients will be followed by phone contact on day 5, day 14 and day 90 after inclusion to get information on antibiotic use, aia and satisfaction scores and clinical outcomes, such urinary infection. data on antibiotics delivery by pharmacy will be obtained through national assurance database.

Eligibility criteria:
inclusion criteria: * woman * between 18 and 65 years * symptom of acute cystitis without risk of complication * affiliated to the french public welfare system * with signed consent exclusion criteria: * anomaly of the urinary canal * pregnancy * more than 3 cystitis during the last year * cancer, immunosuppression * hemopathy, fever * back-pain * severe renal failure * refuse to give consent and previously participate to the study * under guardianship

Keywords: primary health care share decision making antibiotics daily activities
new hampshire medicaid wellness incentive program

Conditions: Tobacco Dependence; Obesity; Mental Illness

Summary: the new hampshire medicaid wellness incentive program (wip) will address both the health disparity and increased costs by providing incentivized health promotion programs to overweight or obese and/or tobacco-smoking medicaid beneficiaries receiving services at new hampshire's 10 regional community mental health centers (cmhcs).

in the new hampshire medicaid wellness incentive program, multiple program options will fall into two categories: (1) supported fitness and weight management and (2) supported smoking cessation. eligible participants are able to participate in 1 or both of the programs. the program options for supported fitness and weight management are: 1. fitness club membership for 12 months, 2. fitness club membership plus weekly meetings with a health mentor for 12 months (in shape), 3. weight watchers membership for 12 months, 4. in shape plus weight watchers for 12 months. the options for supported smoking cessation are: 1. prescriber meeting to discuss smoking cessation treatment options, 2. prescriber meeting plus nh state tobacco helpline, 3. prescriber meeting plus telephone-based cognitive behavioral therapy for smoking cessation. vouchers for memberships to community fitness centers and formal weight loss programs will be provided, as well as incentives for participation and positive outcomes. an equipoise stratified randomization design will be used to preserve the research benefits of randomization while maintaining the highly valued opportunity for consumer choice. research assessments will be conducted at baseline, 3 months, 6 months, 9 months, and 12 months.

Eligibility criteria:
inclusion criteria for smoking intervention and weight management intervention: * participants must be medicaid recipients receiving mental health treatment at one of the participating study sites in new hampshire. * 18 years or older additional inclusion criteria for smoking intervention only: \*smoking 5 or more cigarettes a day or a carbon monoxide level of 5 or higher at screening. additional inclusion criteria for weight management only: \*body mass index of 30 or higher or 25 or higher and sedentary lifestyle. exclusion criteria for both interventions: * diagnosis of dementia or terminal illness (expected to result in death in 1 year or less) * nursing home * inability to speak or understand english additional exclusion criteria for weight management only: * previous participation in the in shape program * active eating disorder diagnosis * pregnancy additional exclusion criteria for smoking intervention only: \*active alcohol or drug dependence with use in the past 30 days

Keywords: tobacco dependence smoking cessation mental health cardiovascular disease obesity
anti-inflammatory effects of colchicine in pci

Conditions: Coronary Artery Disease

Summary: peri-procedural inflammation is associated with increased rates of post-procedural myocardial infarction (mi), which occur in up to 35% of pci patients and are themselves associated with increased risk of later mi and death. statins suppress both inflammatory markers and mi rates during and after pci, but ≥ 40% of pci patients go statin-untreated, due in part to side effects such as myalgia. moreover, because their mechanism of action relies on post-translational effects, statins must be given ≥ 12 to 24 hours prior to pci, a time frame that is not always feasible. the investigators propose a novel alternative approach to reduce inflammation during pci employing colchicine, an anti-inflammatory medication used frequently in gout and pericarditis. colchicine may be particularly applicable to the pci setting due to its rapid onset of action and excellent side-effect profile at low doses, as well as its known mechanisms of action. however, data on colchicine use in patients with coronary disease is extremely limited, and no studies to date have evaluated the use of colchicine in patients undergoing pci. the investigators aim to characterize a potential mechanism of benefit in patients undergoing pci by evaluating the effects of colchicine on soluble and leukocyte surface markers after pci. the investigators also aim to determine the effects of colchicine on peri-procedural myonecrosis and mi. accordingly, the investigators propose a prospective randomized study to characterize the effect of colchicine on inflammation and peri-procedural myocnecrosis. patients referred for possible pci will be randomized in a double-blinded fashion to placebo or colchicine (1.2mg 1 to 2 hours before pci, followed by 0.6mg 1 hour later). the primary endpoint will be post-procedural interleukin-6 level. secondary endpoints will include other relevant soluble and leukocyte-associated inflammatory markers. sample size needed is 200 patients undergoing pci. to adjust for a floor effect, 280 patients undergoing pci will be needed. 400 patients will likely be needed to be enrolled to reach 280 pcis (the remaining will have undergone a diagnostic only procedure). of note, this is a substudy of the colchicine-pci trial (nct 02594111)


Eligibility criteria:
inclusion criteria: * patients must be more than 18 years of age and referred for coronary angiography exclusion criteria: * plan for diagnostic-only coronary angiography * on colchicine chronically * history of intolerance to colchicine * glomerular filtration rate \<30ml/minute or on dialysis * active malignancy or infection * history of myelodysplasia * high-dose statin load \<24 hours prior to procedure * use of oral steroids or non-steroidal anti-inflammatory agents other than aspirin within 72 hours or 3 times the agent's half-life (whichever is longer) * use of strong cyp3a4/p-glycoprotein inhibitors (specifically ritonavir, ketoconazole, clarithromycin, cyclosporine, diltiazem and verapamil) * unable to consent * participating in a competing study
lifestyle intervention program in overweight medical students

Conditions: Overweight

Summary: this study will be a randomized cross-over design over the course of 2 academic years. 40 subjects -20 overweight women and 20 over weight men will be recruited. each subject will have body composition tested, blood lipid profile, and resting metabolic rate done in the beginning of the first academic year and at the end of the first academic year. the intervention group will receive activity trackers, diet counseling, and fitness counseling for one academic year. the second year, all outcome measures (a body scan, blood lipid profile, and resting metabolic rate) will be performed again at the start of the academic year 2, except the intervention group will now be the control group and the control group will now receive the same intervention. all final outcome measures will be performed at the end of the second year.


Eligibility criteria:
inclusion criteria: * male and female nyitcom students between the ages of 18-35 * bmi ≥ 25.0 * body fat % \>19% for males; \>33% for women (will be determined by body composition scan) * own their own smartphone exclusion criteria: * people who have used weight loss smartphone applications in the past 6 month * people who have used an activity tracker in past 6 months * anyone who answers yes to one or more questions on the par-q screen * any contraindication to having a duel x-ray body scan performed based on the american college of radiology's practice guidelines
exploratory study of pagoclone in men with premature ejaculation.

Conditions: Premature Ejaculation

Summary: the purpose of this study is to evaluate pagoclone in the treatment of premature ejaculation.

the primary objective of this study is to evaluate the effect of 3 dose levels of pagoclone (0.15 mg, 0.30 mg, and 0.60 mg) versus placebo on intravaginal ejaculation latency time (ielt) male patients with primary premature ejaculation.

Eligibility criteria:
inclusion criteria: * a male regularly experiencing premature ejaculation * 18 to 55 yrs old * in a stable relationship with one woman for at least 6 months

Keywords: investigational drug ejaculation
effectiveness of cyproheptadine hydrochloride against appetite to improve children's nutritional status

Conditions: Appetite Loss

Summary: the goal of this clinical trial is to learn about the benefits of cyproheptadine hydrochloride in increasing appetite as well as its effect on weight gain in children aged 1-5 years who have difficulty eating. the main questions it aims to answer are: * is cyproheptadine hydrochloride useful in increasing appetite in children? * is the cyproheptadine hydrochloride dose given effective and efficient regarding the improvement of a child's appetite? can giving cyproheptadine hydrochloride improve nutritional status of children? * how long can cyproheptadine hydrochloride be given to increase appetite in children and what are the side effects? participants will: * take the cyproheptadine hydrochloride every day, twice a day for 4 weeks (intervention group); take the placebo (control group) * have their ecast score (score for measuring appetite in children), anthropometric measurement before and after intervention at the second visit (2 weeks), third visit (4 weeks and stop intervention), and fourth visit (8 weeks after stopping the intervention)

this study was conducted in a hospital in the jakarta region, rs citra arafiq. all patients who met the inclusion criteria and had informed consent will be assessed for appetite scoring (ecast) by the research team and diet analysis as a patient baseline before conducting research. scoring of appetite and daily calorie achievement was carried out by the team researcher. all patients underwent anthropometric measurements (body weight, height) carried out by the team. the intervention was carried out for 4 weeks, divided into two groups randomly. during the intervention, caregivers are asked to carry out daily observations and recordings regarding food intake (food records) and weighing 2nd week, 4th week and 8th week. every patient who meets the inclusion criteria receives education regarding correct feeding rules. data taken will be analyzed using ibm statistical product and service solutions (spss).

Eligibility criteria:
inclusion criterias: 1. experiencing decreased appetite and/or difficulty eating 2. poor nutritional status and/or weight faltering 3. the parents agree to participate in the research by signing an informed consent. 4. patients have national health insurance or other health insurance. exclusion criterias: 1. major congenital abnormalities 2. cns disorders (cerebral palsy) 3. inborn errors of metabolism (iem) 4. gerd (gastro esophageal reflux disease) 5. severe acute malnutrition

Keywords: cyproheptadine hydrochloride appetite loss children mild malnutrition
autonomic nervous system reactivity of the newborn after a nociceptive stress: interest of sucrose and non-nutritive sucking

Conditions: Newborn; Neonatal Screening

Summary: the management of the pain is a constant care concern in neonatal and maternity units. many studies show an interest in the use of sugar solutions to reduce nociception during painful events in infants. however, these studies are based mainly on behavioral observation of the newborn but intrinsic mechanisms of analgesic power are not clearly understood for sucrose solutions. our hypothesis is that the analgesic mechanism of sucrose solutions in infants involves a subcortical reactivity notably by action via the brain stem. to explore the intensity of pain and evaluate the subcortical activity, we will use 1) the analysis of heart rate variability (frequency indices whose hfnu) as a peripheral witness of subcortical functioning of the autonomic nervous system 2) electroacoustic analysis of the intensity of crying baby, 3) a composite pain score (dan score).

the investigators want to show that the short term autonomic nervous system (ans) response, after a nociceptive action in the new-born in maternity depends on whether it is preceded by non-nutritive sucking and / or sucrose administration.

Eligibility criteria:
inclusion criteria: * healthy newborn in maternity unit of the saint-etienne university hospital (france), to receive venipuncture for blood tests or neonatal screening test * establishing consent form signed by the holder of parental authority exclusion criteria: * children suffering from a disease affecting the central nervous system. * children treated with paracetamol oral solution (if cephalohematoma for example) or other analgesics (nalbuphine) or sedative, at the time of registration. * newborns impregnated with a prepartum maternal analgesia.

Keywords: newborn neonatal screening autonomic nervous system pain non-nutritive sucking sucrose administration nociceptive action electro acoustical characteristics of crying